A multilayered epithelial mucosa model of head neck squamous cell carcinoma for analysis of tumor-microenvironment interactions and drug development.


Journal

Biomaterials
ISSN: 1878-5905
Titre abrégé: Biomaterials
Pays: Netherlands
ID NLM: 8100316

Informations de publication

Date de publication:
11 2020
Historique:
received: 24 02 2020
revised: 23 06 2020
accepted: 31 07 2020
pubmed: 17 8 2020
medline: 15 5 2021
entrez: 16 8 2020
Statut: ppublish

Résumé

Pharmacotherapy of head and neck squamous cell carcinoma (HNSCC) often fails due to the development of chemoresistance and severe systemic side effects of current regimens limiting dose escalation. Preclinical models comprising all major elements of treatment resistance are urgently needed for the development of new strategies to overcome these limitations. For model establishment, we used tumor cells from patient-derived HNSCC xenografts or cell lines (SCC-25, UM-SCC-22B) and characterized the model phenotype. Docetaxel and cetuximab were selected for comparative analysis of drug-related effects at topical and systemic administration. Cetuximab cell binding was mapped by cluster-based fluorescence lifetime imaging microscopy.The tumor oral mucosa (TOM) models displayed unstructured, hyper-proliferative, and pleomorphic cell layers, reflecting well the original tumor morphology and grading. Dose- and time-dependent effects of docetaxel on tumor size, apoptosis, hypoxia, and interleukin-6 release were observed. Although the spectrum of effects was comparable, significantly lower doses were required to achieve similar docetaxel-induced changes at topical compared to systemic application. Despite displaying anti-proliferative effects in monolayer cultures, cetuximab treatment showed only minor effects in TOM models. This was not due to inefficient cetuximab uptake or target cell binding but likely mediated by microenvironmental components.We developed multi-layered HNSCC models, closely reflecting tumor morphology and displaying complex interactions between the tumor and its microenvironment. Topical application of docetaxel emerged as promising option for HNSCC treatment. Aside from the development of novel strategies for topical drug delivery, our tumor model might help to better understand key regulators of drug-tumor-interactions.

Identifiants

pubmed: 32795620
pii: S0142-9612(20)30523-8
doi: 10.1016/j.biomaterials.2020.120277
pii:
doi:

Substances chimiques

Antibodies, Monoclonal, Humanized 0
Cetuximab PQX0D8J21J

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

120277

Informations de copyright

Copyright © 2020 Elsevier Ltd. All rights reserved.

Auteurs

Leonie Gronbach (L)

Freie Universität Berlin, Institute of Pharmacy (Pharmacology & Toxicology), Königin-Luise-Str. 2+4, 14195, Berlin, Germany.

Christopher Wolff (C)

Freie Universität Berlin, Institute of Pharmacy (Pharmacology & Toxicology), Königin-Luise-Str. 2+4, 14195, Berlin, Germany.

Konrad Klinghammer (K)

Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, And Berlin Institute of Health, Department of Hematology and Oncology, Charitéplatz 1, 10117, Berlin, Germany.

Johannes Stellmacher (J)

Freie Universität Berlin, Institute of Experimental Physics, Arnimallee 14, 14195, Berlin, Germany.

Philipp Jurmeister (P)

Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, And Berlin Institute of Health, Institute of Pathology, Charitéplatz 1, 10117, Berlin, Germany.

Ulrike Alexiev (U)

Freie Universität Berlin, Institute of Experimental Physics, Arnimallee 14, 14195, Berlin, Germany.

Monika Schäfer-Korting (M)

Freie Universität Berlin, Institute of Pharmacy (Pharmacology & Toxicology), Königin-Luise-Str. 2+4, 14195, Berlin, Germany.

Ingeborg Tinhofer (I)

Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, And Berlin Institute of Health, Department of Radiooncology and Radiotherapy, Charitéplatz 1, 10117, Berlin, Germany; German Cancer Research Center (DKFZ), Heidelberg and German Cancer Consortium (DKTK) Partner Site Berlin, Berlin, Germany.

Ulrich Keilholz (U)

Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, And Berlin Institute of Health, Comprehensive Cancer Center, Charitéplatz 1, 10117, Berlin, Germany.

Christian Zoschke (C)

Freie Universität Berlin, Institute of Pharmacy (Pharmacology & Toxicology), Königin-Luise-Str. 2+4, 14195, Berlin, Germany. Electronic address: christian.zoschke@fu-berlin.de.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH